Functionally, nABPD-2 enhances T cell-mediated cytotoxicity against multiple tumor cell lines, including TSCC (CAL27 and CTSC-2), osteosarcoma (MNNG/HOS), and melanoma (A375), outperforming either anti-PD-1 or anti-PD-L1 monoclonal antibodies used alone [67]. The gene discussed is CD274; the disease is neoplasm.